Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Adrenoleukodystrophy

Study Overview
=================
Brief Summary
-----------------
This is a phase I/II, open label dose escalation study of multiple dose levels of NV1205 with a long-term treatment phase.

Detailed Description
-----------------
This study is to evaluate the safety, pharmacokinetics, and efficacy of NV1205 in pediatric patients diagnosed with childhood cerebral adrenoleukodystrophy (CCALD). The study consists of: Screening period: within 30 days of first dose Main treatment period of 12 weeks (Part 1- from Screening to Week 12) Long Term Treatment (LTT) period (Part 2- Week 13 through Week 96) In Part 1, subjects will have an initial 4-week treatment period at the assigned dose and, if no safety concerns are noted, subjects continue for another 8 weeks of extended safety assessment. There will be several cohorts of subjects enrolled. After each Cohort has completed the 4-week initial safety assessment, the safety data will be reviewed by an independent Data Safety Monitoring Board (DSMB) and, subject to DSMB recommendation, Cohort 2 will be enrolled and receive the next dose level. After Cohort 2 has completed 4 weeks of treatment, the DSMB will review all available safety data (Cohorts 1 and 2) and, subject to DSMB recommendation, Cohort 3 will be enrolled and receive the next dose level. Additional Cohorts may be enrolled at the recommendation of the DSMB with an incremental dose increase. In Part 2, subjects will continue to receive treatment in the LTT period of the study.

Official Title
-----------------
Phase I/II, Open-Label, Dose Escalation Study of the Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Childhood Cerebral Adrenoleukodystrophy (CCALD)

Conditions
-----------------
X-Linked Adrenoleukodystrophy

Intervention / Treatment
-----------------
* Drug: Sobetirome (NV1205)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males ≥4 years and <18 years of age CCALD diagnosis confirmed by genetic testing Loes score of >0 and ≤15 Patients on VLCFA lowering agents such as Lorenzo's oil must stop the medication and have high VLCFA levels before enrollment Exclusion Criteria: Significant medical conditions such as heart, thyroid, or liver disease HSCT recipients

Ages Eligible for Study
-----------------
Minimum Age: 4 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Sequential Assignment
Interventional Model Description: Sequential dose escalation
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Sobetirome (NV1205)|Once a day oral dose of the study drug|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 | Adverse events | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Area under the curve concentration of NV1205 in plasma | A sparse sampling approach will be utilized to estimate a 24-hr area under the curve of NV1205 plasma concentration | 12 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
X-ALD